Dynamics of the p53 acetylation pathway

Novartis Foundation Symposium

Volumn 259, Issue , 2004, Pages 197-207

  Gu, Wei ^a   Luo, Jianyuan ^a   Brooks, Chris L ^a   Nikolaev, Anatoly Y ^a   Li, Muyang ^a   Baylin, ^b   Turner, ^b   Pelicci, ^b   Mahadevan, ^b  

^a Columbia University ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; DNA; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; UBIQUITIN;

ACETYLATION; ANIMAL; HUMAN; METABOLISM; REVIEW;

ACETYLATION; ACETYLTRANSFERASES; ANIMALS; DNA; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 2942731801     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (37)

1. Barlev NA, Liu L, Chehab NH et al 2001 Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243-1254
2. Brooks CL, Gu W 2003 Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171
3. Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y 2000 p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 19:4967-4975
4. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW 2000 PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027
5. Freedman DA, Wu L, Levine AJ 1999 Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96-107
6. Frye RA 1999 Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260:273-279
7. Goodman RH, Smolik S 2000 CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577
8. Gray SG, Ekstrom TJ 2001 The human histone deacetylase family. Exp Cell Res 262:75-83
9. Gu W, Roeder RG 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606
10. Gu W, Shi XL, Roeder RG 1997 Synergistic activation of transcription by CBP and p53. Nature 387:819-823
11. Guarente L 2000 Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14:1021-1026
12. Haupt Y, Maya R, Kazaz A, Oren M 1997 Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
13. Honda R, Yasuda H 1999 Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27
14. Hupp TR, Sparks A, Lane DP 1995 Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245
15. Imai S, Armstrong CM, Kaeberlein M, Guarente L 2000 Transcriptional silencing and longevity protein Sir2 is a NAD-dependent histone deacetylase. Nature 403:795-800
16. Ito A, Lai C, Zhao X et al 2001 p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331-1340
17. Jones SN, Roe AE, Donehower LA, Bradley A 1995 Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208
18. Kouzarides T 2000 Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176-1179
19. Langley E, Pearson M, Faretta M et al 2002 Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21:2383-2396
20. Li M, Luo J, Brooks CL, Gu W 2002 Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 277:50607-50611
21. Liu L, Scolnick DM, Trievel RC et al 1999 p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19:1202-1209
22. Luo J, Su F, Chen D, Shiloh A, Gu W 2000 Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377-381
23. Luo J, Nikolaev AY, Imai S et al W 2001 Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148
24. Moazed D 2001 Enzymatic activities of Sir2 and chromatin silencing. Curr Opin Cell Biol 13:232-238
25. Montes de Oca Luna R, Wagner DS, Lozano G 1995 Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206
26. Pearson M, Carbone R, Sebastiani C et al 2000 PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210
27. Pickart CM 2001 Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533
28. Prives C, Hall PA 1999 The p53 pathway. J Pathol 187:112-126
29. Prives C, Manley JL 2001 Why is p53 acetylated? Cell 107:815-818
30. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT 2000 Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20:8458-8467
31. Sakaguchi K, Herrera JE, Saito S et al 1998 DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841
32. Selivanova G, Iotsova V, Okan I et al 1997 Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 6:632-638
33. Sherr CJ, Weber JD 2000 The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99
34. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H 2003 p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5:216-223
35. Vaziri H, Dessain SK, Ng Eaton E et al 2001 hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159
36. Vogelstein B, Lane D, Levine AJ 2000 Surfing the p53 network. Nature 408:307-310
37. Yu A, Fan H, Lao D, Bailey AD, Weiner AM 2000 Activation of p53 or loss of the Cockayne syndrome group B repair protein causes metaphase fragility of human U1, U2, and 5S genes. Mol Cell 5:801-810